Compare AbbVie Inc (ABBV) vs C.H. Robinson Worldwide, Inc. (CHRW) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

C.H. Robinson Worldwide (CHRW) trades at $149.35, up 1.83% on the day, with a bearish technical signal from moving averages but strong profitability metrics including a 37.12% ROE. Recent Q2 2026 earnings beat expectations with EPS of $1.61 versus $1.53 estimated, driven by pricing and efficiency gains. The stock shows support near $146 and resistance at $152, with a consensus analyst price target of $196.00 implying significant upside potential from current levels.

The outlook remains positive based on consistent earnings beats and solid fundamentals, though risks include soft freight demand and rising costs. Analyst sentiment is moderately bullish with 48% buy ratings, but investors should monitor competitive pressures and macroeconomic headwinds that could impact logistics sector performance.